10-Q

Table of Contents ​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

​

​	​
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended December 31, 2023

​

OR

​

​	​
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from **** to ****

​

Commission File Number: 001-36410

Phibro Animal Health Corporation

(Exact name of registrant as specified in its charter)

​

​	​
​	​
Delaware	13-1840497
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
​	​
Glenpointe Centre East, 3rd Floor	​
300 Frank W. Burr Boulevard , Suite 21	​
​	​
Teaneck , New Jersey	07666-6712
(Address of Principal Executive Offices)	(Zip Code)

​

( 201 ) 329-7300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 **** par value per share	​	PAHC ****	​	Nasdaq Stock Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes ☒ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​	​	​	​	​
Large accelerated filer	☐	​	Accelerated filer	☒
Non-accelerated filer	☐	​	Smaller reporting company	☐
Emerging growth company	☐	​	​	​

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

​

As of February 2, 2024, there were 20,337,574 shares of the registrant’s Class A common stock, par value $0.0001 per share, and 20,166,034 shares of the registrant’s Class B common stock, par value $0.0001 per share, outstanding.

​

​

​ ​

Table of Contents PHIBRO ANIMAL HEALTH CORPORATION

TABLE OF CONTENTS

​		Page
PART I—FINANCIAL INFORMATION		​
Item 1.	Financial Statements (unaudited)	3
	Consolidated Statements of Operations	3
	Consolidated Statements of Comprehensive Income (Loss)	4
	Consolidated Balance Sheets	5
	Consolidated Statements of Cash Flows	6
	Consolidated Statements of Changes in Stockholders’ Equity	7
	Notes to Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	36
PART II—OTHER INFORMATION		​
Item 1.	Legal Proceedings	36
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3.	Defaults Upon Senior Securities	36
Item 4.	Mine Safety Disclosures	37
Item 5.	Other Information	37
Item 6.	Exhibits	37
SIGNATURES		38

​

​

​ 2

Table of Contents PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months					****
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022		​
​	​	(unaudited)											​
​	​	(in thousands, except per share amounts)											​
Net sales	​	$	249,943	​	$	244,646	​	$	481,292	​	$	477,167	​
Cost of goods sold	​		171,327	​		167,261	​		334,950	​		331,136	​
Gross profit	​		78,616	​		77,385	​		146,342	​		146,031	​
Selling, general and administrative expenses	​		62,915	​		61,541	​		131,367	​		116,503	​
Operating income	​		15,701	​		15,844	​		14,975	​		29,528	​
Interest expense, net	​		4,659	​		3,884	​		9,223	​		6,951	​
Foreign currency losses (gains), net	​		7,477	​		(149)	​		14,166	​		5,051	​
Income (loss) before income taxes	​		3,565	​		12,109	​		(8,414)	​		17,526	​
Provision (benefit) for income taxes	​		2,291	​		4,899	​		(1,673)	​		6,460	​
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(6,741)	​	$	11,066	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​
Net income (loss) per share	​			​			​			​			​
basic	​	$	0.03	​	$	0.18	​	$	(0.17)	​	$	0.27	​
diluted	​	$	0.03	​	$	0.18	​	$	(0.17)	​	$	0.27	​
Weighted average common shares outstanding	​		​	​		​	​		​	​		​	​
basic	​		40,504	​		40,504	​		40,504	​		40,504	​
diluted	​	​	40,504	​	​	40,504	​	​	40,504	​	​	40,504	​

​

The accompanying notes are an integral part of these consolidated financial statements

​ 3

Table of Contents PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months					****
For the Periods Ended December 31		2023			2022		****	2023			2022		​
​	​	(unaudited)											​
​	​	(in thousands)											​
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(6,741)	​	$	11,066	​
Change in fair value of derivative instruments	​		(4,723)	​		(1,536)	​		(6,614)	​		5,569	​
Foreign currency translation adjustment	​		4,418	​		4,271	​		858	​		128	​
Pension settlement recognition	​	​	249	​	​	—	​	​	10,674	​	​	—	​
Unrecognized net pension gains	​		101	​		192	​		745	​		368	​
Provision (benefit) for income taxes	​		1,196	​		337	​		(1,068)	​		(1,483)	​
Other comprehensive income	​		1,241	​		3,264	​		4,595	​		4,582	​
Comprehensive income (loss)	​	$	2,515	​	$	10,474	​	$	(2,146)	​	$	15,648	​

​

The accompanying notes are an integral part of these consolidated financial statements

​

​ 4

Table of Contents PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

​

​	​	​	​	​	​	​
​	​	December 31,		​	June 30 ,
As of		2023			2023
​	​	(unaudited)
​		(in thousands, except share and per share amounts)
ASSETS	​	​	​	​	​	​
Cash and cash equivalents	​	$	32,970	​	$	41,281
Short-term investments	​		59,523	​		40,000
Accounts receivable, net	​		150,627	​		163,479
Inventories, net	​		286,680	​		277,570
Other current assets	​		56,786	​		63,393
Total current assets	​		586,586	​		585,723
Property, plant and equipment, net	​		200,839	​		195,568
Intangibles, net	​		50,962	​		54,987
Goodwill	​		54,683	​		53,274
Other assets	​		79,638	​		81,845
Total assets	​	$	972,708	​	$	971,397
LIABILITIES AND STOCKHOLDERS' EQUITY	​		​	​		​
Current portion of long-term debt	​	$	26,045	​	$	22,295
Accounts payable	​		86,410	​		73,853
Accrued expenses and other current liabilities	​		75,280	​		79,852
Total current liabilities	​		187,735	​		176,000
Revolving credit facility	​		151,000	​		141,000
Long-term debt	​		297,853	​		311,541
Other liabilities	​		65,317	​		60,347
Total liabilities	​		701,905	​		688,888
Commitments and contingencies (Note 8)	​		​	​		​
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at December 31, 2023, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at December 31, 2023, and June 30, 2023	​		4	​		4
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding	​		—	​	​	—
Paid-in capital	​		135,964	​		135,803
Retained earnings	​		244,450	​		260,912
Accumulated other comprehensive loss	​		(109,615)	​		(114,210)
Total stockholders’ equity	​		270,803	​		282,509
Total liabilities and stockholders’ equity	​	$	972,708	​	$	971,397

​

The accompanying notes are an integral part of these consolidated financial statements

​ 5

Table of Contents PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

​

​	​	​	​	​	​	​	​
​	​	Six Months					​
For the Periods Ended December 31	****	2023		****	2022		​
​	​	(unaudited)					​
​	​	(in thousands)					​
OPERATING ACTIVITIES		​			​		​
Net income (loss)	​	$	(6,741)	​	$	11,066	​
Adjustments to reconcile net income (loss) to	​		​	​		​	​
net cash provided (used) by operating activities:	​		​	​		​	​
Depreciation and amortization	​		17,781	​		16,949	​
Amortization of debt issuance costs	​		520	​		326	​
Deferred income taxes	​		(6,506)	​		(121)	​
Foreign currency losses (gains), net	​		2,355	​		(875)	​
Acquisition-related cost of goods sold	​	​	310	​	​	—	​
Pension settlement cost	​	​	10,674	​	​	—	​
Brazil employment taxes	​	​	4,202	​	​	—	​
Stock-based compensation	​	​	161	​	​	—	​
Other	​		2,513	​		(702)	​
Changes in operating assets and liabilities, net of business acquisition:	​		​	​		​	​
Accounts receivable, net	​		14,316	​		14,839	​
Inventories, net	​		(7,546)	​		(29,082)	​
Other current assets	​		1,934	​		(7,744)	​
Other assets	​		(134)	​		1,035	​
Accounts payable	​		11,543	​		(14,614)	​
Accrued expenses and other liabilities	​		2,375	​		(4,264)	​
Net cash provided (used) by operating activities	​		47,757	​		(13,187)	​
INVESTING ACTIVITIES	​			​			​
Purchases of short-term investments	​		(59,523)	​		(10,000)	​
Maturities of short-term investments	​		40,000			17,000	​
Capital expenditures	​	​	(18,435)			(32,995)	​
Business acquisition, net of cash acquired	​	​	(3,326)	​	​	—	​
Other, net	​		1,071	​		36	​
Net cash used by investing activities	​		(40,213)	​		(25,959)	​
FINANCING ACTIVITIES	​		​	​		​	​
Revolving credit facility borrowings	​		93,000	​		197,000	​
Revolving credit facility repayments	​		(83,000)	​		(158,000)	​
Proceeds from long-term debt	​	​	—	​	​	12,000	​
Payments of long-term debt	​		(10,210)	​		(7,605)	​
Debt issuance costs	​	​	—	​	​	(640)	​
Payments of insurance premium financing	​	​	(3,478)	​	​	—	​
Dividends paid	​		(9,721)	​		(9,720)	​
Net cash (used) provided by financing activities	​		(13,409)	​		33,035	​
Effect of exchange rate changes on cash	​		(2,446)	​		285	​
Net decrease in cash and cash equivalents	​		(8,311)	​		(5,826)	​
Cash and cash equivalents at beginning of period	​		41,281	​		74,248	​
Cash and cash equivalents at end of period	​	$	32,970	​	$	68,422	​

​

The accompanying notes are an integral part of these consolidated financial statements

​ 6

Table of Contents PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

​

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	Accumulated		​	​	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	Other		​	​	​
​	​	Shares of	​	​	​	​	​	​	​	​	​	​	​	​	​	Comprehensive		​	​	​
​	​	Common	​	Common		​	Preferred		​	Paid-in		​	Retained		​	Income		​	​	​
​		Stock		Stock			Stock			Capital			Earnings			(Loss)			Total
​	​	(unaudited)
​	​	(in thousands, except share and per share amounts)
As of June 30, 2023		40,503,608	​	$	4	​	$	—	​	$	135,803	​	$	260,912	​	$	(114,210)	​	$	282,509
Comprehensive income (loss)	​	—	​	​	—	​	​	—	​	​	—	​	​	(8,015)	​	​	3,354	​	​	(4,661)
Dividends declared ($0.12 per share)	​	—	​	​	—	​	​	—	​	​	—	​	​	(4,860)	​	​	—	​	​	(4,860)
Stock-based compensation expense		—		​	—		​	—		​	81		​	—		​	—		​	81
As of September 30, 2023	​	40,503,608	​	$	4	​	$	—	​	$	135,884	​	$	248,037	​	$	(110,856)	​	$	273,069
Comprehensive income	​	—	​	​	—	​	​	—	​	​	—	​	​	1,274	​	​	1,241	​	​	2,515
Dividends declared ($0.12 per share)	​	—	​	​	—	​	​	—	​	​	—	​	​	(4,861)	​	​	—	​	​	(4,861)
Stock-based compensation expense	​	—	​	​	—	​	​	—	​	​	80	​	​	—	​	​	—	​	​	80
As of December 31, 2023		40,503,608	​	$	4	​	$	—	​	$	135,964	​	$	244,450	​	$	(109,615)	​	$	270,803

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	Accumulated		​	​	​
​	​	****	​	​	****	​	​	****	​	​	****	​	​	​	Other		​	​	​
​	Shares of	​	​	​	​	​	​	​	​	​	​	​	​	​	Comprehensive		​	​	​
​	Common	​	Common		​	Preferred		​	Paid-in		​	Retained		​	Income		​	​	​
​	Stock		Stock			Stock			Capital			Earnings			(Loss)			Total
​	(unaudited)
​	(in thousands, except share and per share amounts)
As of June 30, 2022	40,503,608	​	$	4	​	$	—	​	$	135,803	​	$	247,748	​	$	(121,113)	​	$	262,442
Comprehensive income	—	​		—	​		—	​		—	​		3,856	​		1,318	​		5,174
Dividends declared (0.12 per share)	—	​		—	​		—	​		—	​		(4,860)	​		—	​		(4,860)
As of September 30, 2022	40,503,608	​	$	4	​	$	—	​	$	135,803	​	$	246,744	​	$	(119,795)	​	$	262,756
Comprehensive income	—	​	​	—	​	​	—	​	​	—	​	​	7,210	​	​	3,264	​	​	10,474
Dividends declared (0.12 per share)	—	​	​	—	​	​	—	​	​	​	​	​	(4,860)	​	​	—	​	​	(4,860)
As of December 31, 2022	40,503,608	​	$	4	​	$	—	​	$	135,803	​	$	249,094	​	$	(116,531)	​	$	268,370

All values are in US Dollars.

​

The accompanying notes are an integral part of these consolidated financial statements

​

​ 7

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share amounts)

(unaudited)

1.  Description of Business

Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries.

The unaudited consolidated financial information for the three and six months ended December 31, 2023 and 2022, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the “Annual Report”), filed with the Securities and Exchange Commission on August 30, 2023 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of the financial position, results of operations and cash flows of the Company for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2023, was derived from the audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.

The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. Intercompany balances and transactions have been eliminated from the consolidated financial statements. The decision to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity.

​

​

2.  Summary of Significant Accounting Policies and New Accounting Standards

Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of December 31, 2023, there have been no material changes to any of the significant accounting policies contained therein.

Net Income (Loss) per Share and Weighted Average Shares

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period.

Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period after giving effect to dilutive common share equivalents, resulting from the assumed vesting of performance-based restricted stock units, unless the effect would be antidilutive. No common share equivalents were included in the calculation of diluted net income (loss) per share for the three and six months ended December 31, 2023 because the performance-based criteria were not attained in the period.

​ 8

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months					​
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022		****
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(6,741)	​	$	11,066	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​
Weighted average number of shares – basic	​		40,504	​		40,504	​		40,504	​		40,504	​
Dilutive effect of restricted stock units	​	​	—	​	​	—	​	​	—	​	​	—	​
Weighted average number of shares - diluted	​	​	40,504	​	​	40,504	​	​	40,504	​	​	40,504	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​
Net income (loss) per share	​	​	​	​	​	​	​	​	​	​	​	​	​
basic	​	$	0.03	​	$	0.18	​	$	(0.17)	​	$	0.27	​
diluted	​	$	0.03	​	$	0.18	​	$	(0.17)	​	$	0.27	​

​

New Accounting Standards

Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requires the disclosure of significant segment expenses that are included in segment profit or loss and how the segment measures are used for decision-making. The ASU will be effective for Phibro’s fiscal year ending June 30, 2025, including retrospective disclosure for all prior periods presented, and interim periods subsequent to June 30, 2025. We are evaluating both the impact to our segment disclosures and the possibility of early adoption of the ASU.

​

ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU outlines specific categories to be provided in the rate reconciliation and requires additional information for those reconciling items that meet a quantitative threshold. The ASU requires disaggregated disclosure of federal, state and foreign income taxes paid, including disaggregation by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). The ASU also requires disaggregated disclosure of federal, state and foreign income (loss) from continuing operations before income taxes. The enhanced disclosures will be applied on a prospective basis and are required for Phibro’s fiscal year ending June 30, 2026. We are evaluating the impact of the additional income tax-related disclosures.

​

​

3.  Statements of Operations—Additional Information

Disaggregated revenue, deferred revenue and customer payment terms

We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. The products help prevent, control and treat diseases and enhance nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products directly to integrated poultry, cattle and swine customers and through commercial animal feed manufacturers, distributors and veterinarians. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms.

We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

●	MFAs and other: MFAs and other products primarily consist of concentrated medicated products administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include

9

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes antibacterials and other processing aids used in the ethanol fermentation industry.
●	Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.
---	---
●	Vaccines: Vaccine products are primarily focused on preventing diseases in poultry, swine, beef and dairy cattle and aquaculture. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.
---	---

Mineral Nutrition

The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle.

Performance Products

The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type

​

​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022
Animal Health	****	​	****	****	​	****	​	​	****	****	​	****
MFAs and other	​	$	101,941	​	$	97,179	​	$	196,045	​	$	189,969
Nutritional specialties	​		41,436	​		43,856	​		81,646	​		82,910
Vaccines	​		29,727	​		22,768	​		55,943	​		45,783
Total Animal Health	​	$	173,104	​	$	163,803	​	$	333,634	​	$	318,662
Mineral Nutrition	​		61,347	​		61,644	​		117,373	​		121,290
Performance Products	​		15,492	​		19,199	​		30,285	​		37,215
Total	​	$	249,943	​	$	244,646	​	$	481,292	​	$	477,167

​

Net Sales by Region

​

​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022
United States	​	$	140,482	​	$	149,386	​	$	271,769	​	$	285,190
Latin America and Canada	​		65,183	​		53,820	​		123,886	​		106,066
Europe, Middle East and Africa	​		29,518	​		27,827	​		56,397	​		57,344
Asia Pacific	​		14,760	​		13,613	​		29,240	​		28,567
Total	​	$	249,943	​	$	244,646	​	$	481,292	​	$	477,167

​ 10

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net sales by region are based on country of destination.

Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.

Interest Expense, Net

​

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months					​
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022		​
Interest expense, net	​	​	​	​	​	​	​	​	​	​	​	​	​
2021 Credit Facilities	​	$	5,193	​	$	4,252	​	$	10,294	​	$	7,799	​
2022 Term Loan	​	​	217	​	​	188	​	​	433	​	​	188	​
Amortization of debt issuance costs	​		260	​		179	​		520	​		326	​
Other	​		53	​		9	​		121	​		10	​
Interest expense	​		5,723	​		4,628	​		11,368	​		8,323	​
Interest income	​		(1,064)	​		(744)	​		(2,145)	​		(1,372)	​
​	​	$	4,659	​	$	3,884	​	$	9,223	​	$	6,951	​

​

Depreciation and Amortization

​

​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months					​	Six Months
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022
Depreciation and amortization	​		​	​			​		​	​
Depreciation of property, plant and equipment	​	$	6,437	​	$	6,059	​	$	12,868	​	$	12,110
Amortization of intangible assets	​		2,473	​		2,440	​		4,913	​		4,839
​	​	$	8,910	​	$	8,499	​	$	17,781	​	$	16,949

​

Pension Settlement

​

In July 2023, we entered into an annuity purchase agreement to irrevocably transfer a portion of our pension benefit obligation to a third-party insurance company. The annuity purchase price was $26,381 and was approximately equal to the benefit obligation transferred. The annuity purchase was funded from pension assets. We recognized a partial settlement of the pension plan, resulting from the recognition of net pension losses previously included in Accumulated other comprehensive loss. We recorded $249 and $10,674 of expense in selling, general and administrative expenses in our consolidated statement of operations during the three and six months ended December 31, 2023, respectively.

​

4.  Balance Sheets—Additional Information

​

​	​	​	​	​	​	​
​	​	December 31,		​	June 30,
As of		2023			2023
Inventories	​	​	​	​	​
Raw materials	​	$	77,042	​	$	84,328
Work-in-process	​	​	25,066	​	​	22,350
Finished goods	​	​	184,572	​	​	170,892
​	​	$	286,680	​	$	277,570

​ 11

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

​	​	​	​	​	​	​
​		December 31,		​	June 30,
As of		2023			2023
Other assets	​	​	​	​	​	​
ROU operating lease assets	​	$	38,159		$	35,759
Deferred income taxes	​		14,131		​	8,711
Deposits	​		2,372		​	6,617
Insurance investments	​		6,157		​	6,067
Equity method investments	​		5,376		​	5,027
Derivative instruments	​	​	4,382	​	​	10,225
Debt issuance costs	​		1,159		​	1,408
Other	​	​	7,902	​	​	8,031
​	​	$	79,638		$	81,845

​

​	​	​	​	​	​	​
​		December 31,			June 30,
As of		2023			2023
Accrued expenses and other current liabilities		​			​
Employee related	​	$	27,428	​	$	29,359
Current operating lease liabilities	​		7,003	​		6,053
Commissions and rebates	​	​	5,344	​	​	5,833
Professional fees	​		6,329	​		5,032
Income and other taxes	​	​	5,763	​	​	8,663
Insurance-related	​		1,362	​		1,284
Insurance premium financing	​	​	1,159	​	​	4,769
Other	​		20,892	​		18,859
​	​	$	75,280	​	$	79,852

​

​	​	​	​	​	​	​
​		December 31,			June 30,
As of		2023			2023
Other liabilities	​	​	​	​	​	​
Long-term operating lease liabilities	​	$	31,193	​	$	29,077
Long-term and deferred income taxes	​		14,230	​	​	12,146
Supplemental retirement benefits, deferred compensation and other	​	​	6,704	​	​	6,552
U.S. pension plan	​		1,672	​		2,286
International retirement plans	​		4,379	​		4,210
Other long-term liabilities	​		7,139	​		6,076
​	​	$	65,317	​	$	60,347

​

​	​	​	​	​	​	​
​	​	December 31,		****	June 30,
As of		2023			2023
Accumulated other comprehensive loss	​	​		​	​
Derivative instruments	​	$	17,975	​	$	24,589
Foreign currency translation adjustment	​		(114,204)	​		(115,062)
Unrecognized net pension losses	​		(12,577)	​		(23,996)
Income tax (provision) benefit	​		(809)	​		259
​	​	$	(109,615)	​	$	(114,210)

​

5.  Debt

Term Loans and Revolving Credit Facilities

In April 2021, we entered into an amended and restated credit agreement (the “2021 Credit Agreement”) under which we had a term A loan in an aggregate initial principal amount of $300,000 (the “2021 Term A Loan”) and a revolving credit facility under 12

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

which we could borrow up to an aggregate amount of $250,000, subject to the terms of the 2021 Credit Agreement (the “2021 Revolver”). In November 2022, we amended the 2021 Credit Facilities to increase the revolving commitments under the 2021 Revolver to an aggregate amount of $310,000 and to adopt Secured Overnight Financing Rate (“SOFR”) as the reference for the fluctuating rate of interest on the 2021 Credit Facilities, replacing the London Interbank Offered Rate (“LIBOR”) reference rate. In June 2023, we obtained an additional incremental term loan (the “2023 Incremental Term Loan”) in the amount of $50,000 (the 2021 Revolver, the 2021 Term A Loan and the 2023 Incremental Term Loan are collectively referred to as the “2021 Credit Facilities”).

The 2021 Term A Loan and the 2023 Incremental Term Loan are repayable in quarterly installments, with the balances payable at maturity. The 2021 Revolver contains a letter of credit facility. The interest rate per annum applicable to the 2021 Revolver and the 2021 Term A Loan is based on a fluctuating rate of interest plus an applicable rate equal to 1.50%, 1.75%, 2.00% or 2.25%, in the case of adjusted SOFR rate loans and 0.50%, 0.75%, 1.00% or 1.25%, in the case of base rate loans. The interest rate per annum applicable to the 2023 Incremental Term Loan is based on a fluctuating rate of interest plus an applicable rate equal to 2.00%, 2.25%, 2.50% or 2.75%, in the case of adjusted SOFR rate loans and 1.00%, 1.25%, 1.50% or 1.75%, in the case of base rate loans. The applicable rates are based on the First Lien Net Leverage Ratio (as defined in the 2021 Credit Agreement, as amended). The 2021 Credit Facilities mature in April 2026.

The 2021 Credit Agreement requires, among other things, compliance with financial covenants that permit: (i) a maximum First Lien Net Leverage Ratio of 4.00:1.00 (or, specifically with respect to the test periods ending December 31, 2023, March 31, 2024, and June 30, 2024, a maximum of 4.25:1.00); and (ii) a minimum interest coverage ratio of 3.00:1.00, each calculated on a trailing four-quarter basis. The 2021 Credit Agreement contains an acceleration clause should an event of default (as defined in the 2021 Credit Agreement) occur. As of December 31, 2023, we were in compliance with the financial covenants.

As of December 31, 2023, we had $151,000 in borrowings drawn under the 2021 Revolver and had outstanding letters of credit of $2,479, leaving $156,521 available for further borrowings and letters of credit under the 2021 Revolver, subject to restrictions in our 2021 Credit Facilities. We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The terms of these letters of credit are all less than one year.

Interest Rates

Interest rates as of the balance sheet dates and the weighted-average rates for the periods presented were:

​

​	​	​	​	​	​	​	​	​	​	​
​		​	​	​	​	​	Six Months
​	​	December 31,		June 30,		​	Ended December 31
​	​	2023		2023		​	2023	​	2022	​
2021 Revolver		6.14	%	6.09	%		6.19	%	4.57	%
2021 Term A Loan	​	2.36	%	2.36	%	​	2.36	%	2.37	%
2023 Incremental Term Loan	​	7.73	%	7.44	%	​	7.62	%	—	​
2022 Term Loan	​	7.46	%	7.25	%	​	7.39	%	5.74	%

​

Interest rates as of the balance sheet dates are based on rates in effect as of those dates, including SOFR fluctuating rates of interest, applicable rates and the interest rate swap agreement.

We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We designated the interest rate swap as a highly effective cash flow hedge. For additional details, see “Note 9 — Derivatives.” 13

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Other Long-Term Debt

​

In September 2022, we entered into a credit agreement (the “2022 Term Loan”) in the amount of $12,000, collateralized by certain facilities. The 2022 Term Loan matures in September 2027. The interest rate per annum applicable to the 2022 Term Loan is based on a fluctuating rate of interest, at the Company’s election from time to time, equal to either (i) one-month adjusted SOFR plus 2.00%, or (ii) a base rate determined by reference to the greater of (a) the prime rate and (b) the Federal Funds Effective Rate plus 0.50%. The 2022 Term Loan is repayable in monthly installments of $35, with the balance payable at maturity.

​

Maturities of Long-Term Debt

​

​	​	​	​	​	​	​
​		December 31,		​	June 30,
As of	​	2023		​	2023
2021 Term A Loan due April 2026	​	$	266,250	​	$	273,750
2023 Incremental Term Loan due April 2026	​	​	47,500	​	​	50,000
2022 Term Loan due September 2027	​		11,475	​		11,685
​	​		325,225	​		335,435
Unamortized debt issuance costs	​		(1,327)	​		(1,599)
​	​		323,898	​		333,836
Less: current maturities	​		(26,045)	​		(22,295)
​	​	$	297,853	​	$	311,541

​

​

6.  Related Party Transactions

Certain relatives of Jack C. Bendheim, our Chairman, President and Chief Executive Officer, provided services to the Company as employees or consultants and received aggregate compensation and benefits of approximately $378 and $397 during the three months ended December 31, 2023 and 2022, and $817 and $1,177 during the six months ended December 31, 2023 and 2022, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

7. Stock Incentive Plan

Restricted Stock Units

In July 2023, our Board of Directors approved the grant of 300,000 restricted stock units (“RSUs”) to an officer of the Company, pursuant to the Company's 2008 Incentive Plan and the RSU award agreement. Each RSU represents the right to receive a share of our common stock upon vesting. The RSUs are subject to performance-based vesting. The RSUs will vest on June 30, 2027, subject to continuation of employment on such date, in increments of 10% (but no less than 20%) (with linear interpolation between increments) based upon the arithmetic average of the Company’s closing stock price per share for each trading day in the 90-calendar day period ending on the vesting date (the “90-Day Average”). None of the RSUs will vest if the 90-Day Average is below $20, and 100% of the RSUs will vest if the 90-Day Average is $60 or above. In the event of a change in control of the Company, following which either (i) 100% of the shares of stock cease to be traded on a nationally recognized stock exchange and the Company is no longer listed on any such exchange or (ii) a Qualifying Termination occurs within 12 months, all unvested RSUs will immediately vest in full.

We used a Monte Carlo simulation model to determine the grant date fair value of the RSUs. Assumptions used by the model were based on information as of the grant date and included a risk-free rate of return, expected volatility and an expected dividend yield. The risk-free rate of return is based on U.S. treasury yields for bonds with similar maturities. Expected volatility is based on the historical volatility of the Company’s common stock. The expected dividend yield considers estimated annual dividends and the closing share price of the underlying common stock. 14

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The total grant date fair value of the RSUs was $1,284, equivalent to $4.28 per share. We will recognize the total grant date fair value of the RSUs as stock-based compensation expense on a straight-line basis over the vesting period. Stock-based compensation expense related to the RSUs was $80 and $161 for the three and six months ended December 31, 2023, respectively. We expect stock-based compensation expense related to the RSUs will be $321 in each of the years ending June 30, 2024, 2025, 2026 and 2027.

8.  Commitments and Contingencies

Environmental

Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination, and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the period during which such costs are likely to be incurred are difficult to predict.

While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.

The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based on our experience, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of the Santa Fe Springs, California facility of our subsidiary, Phibro-Tech, Inc. (“Phibro-Tech”). The EPA has entered into a settlement agreement with a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling (“OPOG”) to remediate the contaminated groundwater that has migrated from the Omega Chemical Site in accordance with a general remedy selected by the EPA. The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that any groundwater contamination at its site is localized and due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. PAHC and Phibro-Tech have vigorously contested this position and have asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. In 2014, 15

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

several members of OPOG filed a complaint under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”) and the Resource Conservation and Recovery Act in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. In August 2022, the United States Department of Justice (the “DOJ”), on behalf of the EPA, sent Phibro-Tech and certain other PRPs a pre-litigation notice letter regarding potential CERCLA Sec. 107 cost recovery claims seeking unrecovered past costs related to the groundwater plume affected by the Omega Chemical Site, along with a declaration allocating liability for future costs.

In February 2023, the plaintiffs in the OPOG lawsuit and certain defendants in the OPOG lawsuit, including Phibro-Tech, signed a definitive settlement agreement that provides for a “cash-out” settlement, with contribution protection, for Phibro-Tech and its affiliates (as well as certain other defendants) releasing Phibro-Tech and its affiliates from liability for contamination of the groundwater plume affected by the Omega Chemical Site (with certain exceptions), including past and future EPA response costs that were the subject of the August 2022 pre-litigation notice letter sent by the DOJ on behalf of the EPA. As part of the settlement, Phibro-Tech also resolved all claims for indemnification and contribution between Phibro-Tech and the successor to the prior owner of the Phibro-Tech site. The definitive settlement agreement contemplates cash payments by Phibro-Tech and one of its affiliates over a period ending in February 2024. The definitive settlement agreement is subject to formal approval by the EPA, the DOJ and the district court.

​

Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, including the remaining liability for the OPOG lawsuit described in the preceding paragraph, to be approximately $8,475 and $8,505 at December 31, 2023 and June 30, 2023, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries are liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.

Claims and Litigation

PAHC and its subsidiaries are party to various claims and lawsuits arising out of the normal course of business including product liabilities, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

​

9.  Derivatives

We monitor our exposure to foreign currency exchange rates and interest rates and from time-to-time use derivatives to manage certain of these risks. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). All changes in the fair value of a highly effective cash flow hedge are recorded in Accumulated other comprehensive income (loss).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see “Note 10 — Fair Value Measurements.” 16

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We are a party to an interest rate swap agreement on $300,000 of notional principal that effectively converts the floating SOFR portion of our interest obligation on that amount of debt to a fixed rate of 0.61% through June 2025. We designated the interest rate swap as a highly effective cash flow hedge.

The consolidated balance sheet includes the net fair values of our outstanding foreign currency option contracts within the respective line items, based on the net financial position and maturity date of the individual contracts. The consolidated balance sheet includes the net fair values of our outstanding interest rate swap within the respective balance sheet line items, based on the expected timing of the cash flows. The consolidated balance sheet includes assets and liabilities for the fair values of outstanding derivatives that are designated and effective as cash flow hedges as follows:

​

​	​	​	​	​	​	​
​	​	December 31,		​	June 30,
As of	****	2023		****	2023
Other current assets		​			​
Foreign currency option contracts, net	​	$	1,422	​	$	333
Interest rate swap	​		12,349	​		14,031
Other assets	​	​	​	​	​	​
Interest rate swap	​	​	4,382	​	​	10,225
Total Fair Value	​		​	​		​
Foreign currency option contracts, net	​		1,422	​		333
Interest rate swap	​		16,731	​		24,256

​

Notional amounts of the derivatives as of the balance sheet date were:

​

​	​	​	​
​	​	December 31,
As of	****	2023
Interest rate swap	​	$	300,000
Brazil Real-USD call options	​	R$	36,000
Brazil Real-USD put options	​	R$	(36,000)
USD-Israel shekel call options	​	$	(18,656)
USD-Israel shekel put options	​	$	18,656

​

The consolidated statements of operations and statements of comprehensive income for the periods ended December 31, 2023 and 2022 included the effects of derivatives as follows:

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	Three Months					****	Six Months					​
For the Periods Ended December 31	​	2023		****	2022		****	2023		****	2022		​
Foreign currency option contracts, net		​			​		​	​			​		​
(Income) expense recorded in consolidated statements of operations	​	$	(390)	​	$	355	​	$	(571)	​	$	792	​
Consolidated statement of operations - total cost of goods sold	​	$	171,327	​	$	167,261	​	$	334,950	​	$	331,136	​
Consolidated statement of operations - total selling, general and administrative expenses	​	$	62,915	​	$	61,541	​	$	131,367	​	$	116,503	​
(Income) expense recorded in comprehensive income (loss)	​	$	(1,243)	​	$	(18)	​	$	(910)	​	$	150	​
Interest rate swap	​		​	​		​	​		​	​		​	​
(Income) recorded in consolidated statements of operations	​	$	(3,643)	​	$	(2,298)	​	$	(7,213)	​	$	(3,508)	​
Consolidated statement of operations - total interest expense, net	​	$	4,659	​	$	3,884	​	$	9,223	​	$	6,951	​
(Income) expense recorded in comprehensive income (loss)	​	$	5,966	​	$	1,554	​	$	7,524	​	$	(5,719)	​

​

We recognize gains and losses related to certain foreign currency derivatives as a component of cost of goods sold at the time the hedged item is sold. Inventory as of December 31, 2023, included realized net gains of $1,317 related to matured contracts. We anticipate the net gains included in inventory will be recognized in cost of goods sold within the next twelve to eighteen months.

​ 17

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

10.  Fair Value Measurements

Short-term Investments

Our short-term investments consist of cash deposits held at financial institutions. We consider the carrying amounts of these short-term investments to be representative of their fair value.

Current Assets and Liabilities

We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.

Debt

We record debt, including term loans and revolver balances, at amortized cost in our consolidated financial statements. We believe the carrying value of the debt is approximately equal to its fair value, due to the variable nature of the instruments and our evaluation of estimated market prices.

Derivatives

We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency exchange rates.

Non-financial Assets

Our non-financial assets, which primarily consist of goodwill, other intangible assets, property and equipment, and lease-related right-of-use (“ROU”) assets, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in the consolidated balance sheet. Assets and liabilities may be required to be measured at fair value on a non-recurring basis, either upon initial recognition or for subsequent accounting or reporting, including the initial recognition of net assets acquired in a business combination. These fair value measurements involve unobservable inputs that reflect estimates and assumptions that represent Level 3 inputs.

Fair Value of Assets (Liabilities)

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
As of	​	December 31, 2023								​	June 30, 2023
​		Level 1		****	Level 2		****	Level 3		****	Level 1		****	Level 2		****	Level 3
Short-term investments	​	$	59,523	​	$	—	​	$	—	​	$	40,000	​	$	—	​	$	—
Foreign currency derivatives	​	$	—	​	$	1,422	​	$	—	​	$	—	​	$	333	​	$	—
Interest rate swap	​	$	—	​	$	16,731	​	$	—	​	$	—	​	$	24,256	​	$	—

​

There were no transfers between levels during the periods presented.

​

​

11.  Business Segments

We evaluate performance and allocate resources, based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, business technology, legal, finance, human resources and business development. The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein. 18

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We evaluate performance of our segments based on Adjusted EBITDA. We calculate Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (e) certain items that we consider to be unusual, non-operational or non-recurring.

​

​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	Three Months					****	Six Months
For the Periods Ended December 31	****	2023		****	2022		****	2023		****	2022
Net sales
Animal Health	​	$	173,104	​	$	163,803	​	$	333,634	​	$	318,662
Mineral Nutrition	​		61,347	​		61,644	​		117,373	​		121,290
Performance Products	​		15,492	​		19,199	​		30,285	​		37,215
Total segments	​	$	249,943	​	$	244,646	​	$	481,292	​	$	477,167
​	​	​	​	​	​	​	​	​	​	​	​	​
Depreciation and amortization	​	​	​	​	​	​	​	​	​	​	​	​
Animal Health	​	$	7,348	​	$	6,934	​	$	14,697	​	$	13,845
Mineral Nutrition	​		660	​		659	​		1,306	​		1,314
Performance Products	​		433	​		453	​		859	​		895
Total segments	​	$	8,441	​	$	8,046	​	$	16,862	​	$	16,054
Adjusted EBITDA	​	​	​	​	​	​	​	​	​	​	​	​
Animal Health	​	$	39,299	​	$	37,059	​	$	67,793	​	$	64,023
Mineral Nutrition	​		3,507	​		4,399	​		6,388	​		9,696
Performance Products	​		817	​		2,292	​		2,226	​		4,656
Total segments	​	$	43,623	​	$	43,750	​	$	76,407	​	$	78,375
Reconciliation of income (loss) before income taxes to Adjusted EBITDA	​	​	​	​	​	​	​	​	​	​	​	​
Income (loss) before income taxes	​	$	3,565	​	$	12,109	​	$	(8,414)	​	$	17,526
Interest expense, net	​		4,659	​		3,884	​		9,223	​		6,951
Depreciation and amortization – Total segments	​		8,441	​		8,046	​		16,862	​		16,054
Depreciation and amortization – Corporate	​		469	​		453	​		919	​		895
Corporate costs	​	​	14,171	​	​	12,838	​	​	28,304	​	​	25,329
Acquisition-related cost of goods sold	​	​	310	​	​	—	​	​	310	​	​	—
Pension settlement cost	​	​	249	​	​	—	​	​	10,674	​	​	—
Brazil employment taxes	​	​	4,202	​	​	—	​	​	4,202	​	​	—
Stock-based compensation	​	​	80	​	​	—	​	​	161	​	​	—
Environmental remediation costs	​	​	—	​	​	6,569	​	​	—	​	​	6,569
Foreign currency losses (gains), net	​		7,477	​		(149)	​		14,166	​		5,051
Adjusted EBITDA – Total segments	​	$	43,623	​	$	43,750	​	$	76,407	​	$	78,375

19

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

​

​	​	​	​	​	​	​
​	​	December 31,		****	June 30,
As of	****	2023		****	2023
Identifiable assets		​			​
Animal Health	​	$	694,383	​	$	698,522
Mineral Nutrition	​		71,755	​		75,814
Performance Products	​		48,879	​		49,678
Total segments	​		815,017	​		824,014
Corporate	​		157,691	​		147,383
Total	​	$	972,708	​	$	971,397

​

The Animal Health segment includes all goodwill of the Company. Corporate assets include cash and cash equivalents, short-term investments, debt issuance costs, income tax-related assets and certain other assets.

​

​

​

​

​

​ 20

Table of Contents ​

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” in Item 1A of our Annual Report and “Forward-Looking Statements.”

Overview of our business

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Armed Conflicts

Hamas and Israel

On October 7, 2023, Hamas militants crossed into Israel from Gaza in a large-scale, surprise terrorist attack. Hamas terrorists invaded Israel, first firing rockets into the country and then carrying out attacks inflicting mass casualties with hundreds more taken hostage. In order to provide immediate assistance to the victims of the attacks and their families, we and our employees provided monetary donations that were distributed to charities that offered relief services, welfare, equipment, food and other necessities.

We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of December 31, 2023, we had approximately 500 employees located in Israel. While we initially had some disruption to our operations at the onset of the conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years.

The prolonged continuation or escalation of this conflict may trigger bans, economic and other sanctions, as well as broader military conflict, which could include neighboring nations. The potential impact of the current conflict, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 27% of our consolidated assets as of December 31, 2023, and 19% of our consolidated net sales, for the six months ended December 31, 2023.

Russia and Ukraine

In response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and technical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia. 21

Table of Contents Since the conflict began, the United States and other North Atlantic Treaty Organization (“NATO”) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the twelve months ended December 31, 2023, represented approximately 1% of consolidated net sales.

We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations.

Regulatory developments

In April 2016, the Food and Drug Administration (“FDA”) began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (“NOOH”), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDA’s Center for Veterinary Medicine (“CVM”) inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method.

In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the extensive research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting residues of carbadox. The FDA also provided notice in the Federal Register proposing to withdraw approval of all new animal drug applications (NADAs) providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVM’s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is taking the next steps to continue to defend swine producers’ ability to use Mecadox. We have formally requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the twelve months ended December 31, 2023 were approximately $18 million. As of the date of the filing of this Quarterly Report on Form 10-Q, Mecadox continues to be available for use by swine producers. For additional information, see also “Business — Compliance with Government Regulation — United States — Carbadox”; and “Business — Compliance with Government Regulation — Global Policy and Guidance” in Item 1 of our Annual Report. 22

Table of Contents Analysis of the consolidated statements of operations

Summary Results of Operations

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months										​	​	Six Months										​
For the Periods Ended December 31	****	2023		****	2022		****	Change				****	****	2023		****	2022		****	Change				​
​	​	(in thousands, except per share amounts and percentages)																						​
Net sales	****	$	249,943	**** ​	$	244,646	****	$	5,297	****	2	%	​	$	481,292	****	$	477,167	****	$	4,125	****	1	%
Gross profit	​		78,616	​		77,385	​		1,231	​	2	%	​		146,342	​		146,031	​		311	​	0	%
Selling, general and administrative expenses	​		62,915	​		61,541	​		1,374	​	2	%	​		131,367	​		116,503	​		14,864	​	13	%
Operating income	​		15,701	​		15,844	​		(143)	​	(1)	%	​		14,975	​		29,528	​		(14,553)	​	*	​
Interest expense, net	​		4,659	​		3,884	​		775	​	20	%	​		9,223	​		6,951	​		2,272	​	33	%
Foreign currency losses (gains), net	​		7,477	​		(149)	​		7,626	​	*	​	​		14,166	​		5,051	​		9,115	​	*	​
Income (loss) before income taxes	​		3,565	​		12,109	​		(8,544)	​	(71)	%	​		(8,414)	​		17,526	​		(25,940)	​	*	​
Provision (benefit) for income taxes	​		2,291	​		4,899	​		(2,608)	​	(53)	%	​		(1,673)	​		6,460	​		(8,133)	​	*	​
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(5,936)	​	(82)	%	​	$	(6,741)	​	$	11,066	​	$	(17,807)	​	*	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Net income (loss) per share	​			​		​	​		​		​	​	​			​		​	​		​	​	​	​
Basic	​	$	0.03	​	$	0.18	​	$	(0.15)	​	(82)	%	​	$	(0.17)	​	$	0.27	​	$	(0.44)	​	*	​
Diluted	​	$	0.03	​	$	0.18	​	$	(0.15)	​	(82)	%	​	$	(0.17)	​	$	0.27	​	$	(0.44)	​	*	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Weighted average number of shares outstanding	​			​		​	​			​	​	​	​			​		​	​			​	​	​
Basic	​		40,504	​		40,504	​			​	​	​	​		40,504	​		40,504	​			​	​	​
Diluted	​	​	40,504	​	​	40,504	​	​	​	​	​	​	​	​	40,504	​	​	40,504	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Ratio to net sales	​			​		​	​			​	​	​	​			​		​	​			​	​	​
Gross profit	​		31.5	%		31.6	%			​	​	​	​		30.4	%		30.6	%			​	​	​
Selling, general and administrative expenses	​		25.2	%		25.2	%			​	​	​	​		27.3	%		24.4	%			​	​	​
Operating income	​		6.3	%		6.5	%			​	​	​	​		3.1	%		6.2	%			​	​	​
Income (loss) before income taxes	​		1.4	%		4.9	%			​	​	​	​		(1.7)	%		3.7	%			​	​	​
Net income (loss)	​		0.5	%		2.9	%			​	​	​	​		(1.4)	%		2.3	%		​	​	​	​
Effective tax rate	​		64.3	%		40.5	%			​	​	​	​		19.9	%		36.9	%			​	​	​

Certain amounts and percentages may reflect rounding adjustments.

*	Calculation not meaningful

Net sales, Adjusted EBITDA and reconciliation of GAAP net income (loss) to Adjusted EBITDA

We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures.” 23

Table of Contents Segment net sales and Adjusted EBITDA:

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months										​	​	Six Months										​
For the Periods Ended December 31	****	2023		****	2022		****	Change				****	​	2023		****	2022		****	Change				​
Net sales	​	(in thousands, except percentages)																						​
MFAs and other	​	$	101,941	​	$	97,179	​	$	4,762		5	%	​	$	196,045	​	$	189,969	​	$	6,076	​	3	%
Nutritional specialties	​		41,436	​		43,856	​		(2,420)		(6)	%	​		81,646	​		82,910	​		(1,264)	​	(2)	%
Vaccines	​		29,727	​		22,768	​		6,959		31	%	​		55,943	​		45,783	​		10,160	​	22	%
Animal Health	​		173,104	​		163,803	​		9,301		6	%	​		333,634	​		318,662	​		14,972	​	5	%
Mineral Nutrition	​		61,347	​		61,644	​		(297)		(0)	%	​		117,373	​		121,290	​		(3,917)	​	(3)	%
Performance Products	​		15,492	​		19,199	​		(3,707)		(19)	%	​		30,285	​		37,215	​		(6,930)	​	(19)	%
Total	​	$	249,943	​	$	244,646	​	$	5,297		2	%	​	$	481,292	​	$	477,167	​	$	4,125	​	1	%
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Adjusted EBITDA	​			​			​					​	​			​			​			​	​	​
Animal Health	​	$	39,299	​	$	37,059	​	$	2,240		6	%	​	$	67,793	​	$	64,023	​	$	3,770	​	6	%
Mineral Nutrition	​		3,507	​		4,399	​		(892)		(20)	%	​		6,388	​		9,696	​		(3,308)	​	(34)	%
Performance Products	​		817	​		2,292	​		(1,475)		(64)	%	​		2,226	​		4,656	​		(2,430)	​	(52)	%
Corporate	​		(14,171)	​		(12,838)	​		(1,333)		10	%	​		(28,304)	​		(25,329)	​		(2,975)	​	12	%
Total	​	$	29,452	​	$	30,912	​	$	(1,460)		(5)	%	​	$	48,103	​	$	53,046	​	$	(4,943)	​	(9)	%
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Adjusted EBITDA as a percentage of segment net sales	​			​		​	​					​	​			​		​	​			​	​	​
Animal Health	​		22.7	%		22.6	%					​	​		20.3	%		20.1	%			​	​	​
Mineral Nutrition	​		5.7	%		7.1	%					​	​		5.4	%		8.0	%			​	​	​
Performance Products	​		5.3	%		11.9	%					​	​		7.4	%		12.5	%			​	​	​
Corporate ^(1)^	​		(5.7)	%		(5.2)	%					​	​		(5.9)	%		(5.3)	%			​	​	​
Total ^(1)^	​		11.8	%		12.6	%					​	​		10.0	%		11.1	%			​	​	​
(1)	Reflects ratio to total net sales
---	---

The table below sets forth a reconciliation of net income (loss), as reported under GAAP, to Adjusted EBITDA:

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	Three Months										​	​	Six Months										​
For the Periods Ended December 31	****	2023		****	2022		****	Change				****	​	2023		****	2022		****	Change				​
​	​	(in thousands, except percentages)																						​
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(5,936)	**** ​	(82)	%	​	$	(6,741)	​	$	11,066	​	$	(17,807)	****	*	​
Interest expense, net	​	​	4,659	​	​	3,884	​	​	775	​	20	%	​	​	9,223	​	​	6,951	​	​	2,272	​	33	%
Provision (benefit) for income taxes	​	​	2,291	​	​	4,899	​	​	(2,608)	​	(53)	%	​	​	(1,673)	​	​	6,460	​	​	(8,133)	​	*	​
Depreciation and amortization	​	​	8,910	​	​	8,499	​	​	411	​	5	%	​	​	17,781	​	​	16,949	​	​	832	​	5	%
EBITDA	​	​	17,134	​	​	24,492	​	​	(7,358)	​	(30)	%	​	​	18,590	​	​	41,426	​	​	(22,836)	​	(55)	%
Acquisition-related cost of goods sold	​	​	310	​	​	—	​	​	310	​	*	​	​	​	310	​	​	—	​	​	310	​	*	​
Pension settlement cost		​	249		​	—		​	249		*	​	​	​	10,674		​	—		​	10,674	​	*	​
Brazil employment taxes	​	​	4,202	​	​	—	​	​	4,202	​	*	​	​	​	4,202	​	​	—	​	​	4,202	​	*	​
Stock-based compensation	​	​	80	​	​	—	​	​	80		*	​	​	​	161	​	​	—	​	​	161	​	*	​
Environmental remediation costs	​	​	—	​	​	6,569	​	​	(6,569)		*	​	​	​	—	​	​	6,569	​	​	(6,569)	​	*	​
Foreign currency losses (gains), net	​	​	7,477		​	(149)		​	7,626		*	​	​	​	14,166		​	5,051		​	9,115	​	*	​
Adjusted EBITDA	​	$	29,452	​	$	30,912	​	$	(1,460)		(5)	%	​	$	48,103	​	$	53,046	​	$	(4,943)	​	(9)	%

Certain amounts may reflect rounding adjustments.

* Calculation not meaningful 24

Table of Contents

Adjusted net income

We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. See “—General description of non-GAAP financial measures.” The table below sets forth a reconciliation of net income (loss), as reported under GAAP, to adjusted net income:

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	Three Months										​	Six Months
For the Periods Ended December 31		2023		****	2022			Change					2023		****	2022		****	Change
​	​	(in thousands, except per share amounts and percentages)
Net income (loss)	​	$	1,274	​	$	7,210	​	$	(5,936)		(82)	%	$	(6,741)	​	$	11,066	​	$	(17,807)		*	​
Acquisition-related intangible amortization ^(1)^	​		1,670	​		1,657	​		13		1	%		3,344	​		3,314	​		30		1	%
Acquisition-related intangible amortization^(2)^	​		803	​		781	​		22		3	%		1,569	​		1,520	​		49		3	%
Acquisition-related cost of goods sold ^(1)^	​	​	310	​	​	—	​	​	310	​	*	​	​	310	​	​	—	​	​	310	​	*	​
Pension settlement cost ^(2)^	​	​	249	​	​	—	​	​	249	​	*	​	​	10,674	​	​	—	​	​	10,674		*	​
Brazil employment taxes ^(2)^	​	​	4,202	​	​	—	​	​	4,202	​	*	​	​	4,202	​	​	—	​	​	4,202	​	*	​
Stock-based compensation ^(2)^	​	​	80	​	​	—	​	​	80	​	*	​	​	161	​	​	—	​	​	161	​	*	​
Environmental remediation costs ^(2)^	​	​	—	​	​	6,569	​	​	(6,569)	​	*	​	​	—	​	​	6,569	​	​	(6,569)	​	*	​
Foreign currency losses (gains), net ^(3)^	​		7,477	​		(149)	​		7,626		*	​		14,166	​		5,051	​		9,115		*	​
Adjustments to income taxes ^(4)^	​		(2,606)	​		(2,284)	​		(322)		*	​		(8,686)	​		(5,409)	​		(3,277)		*	​
Adjusted net income	​	$	13,459	​	$	13,784	​	$	(325)		(2)	%	$	18,999	​	$	22,111	​	$	(3,112)		(14)	%
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Statement of Operations Line Items - adjusted	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Adjusted cost of goods sold ^(1)^	​	$	169,346	​	$	165,604	​	$	3,742		2	%	$	331,296	​	$	327,822	​	$	3,474		1	%
Adjusted gross profit	​		80,596	​		79,042	​		1,554		2	%		149,996	​		149,345	​		651	​	0	%
Adjusted selling, general and administrative ^(2)^	​		57,582	​		54,191	​		3,391		6	%		114,761	​		108,414	​		6,347		6	%
Adjusted interest expense, net	​		4,659	​		3,884	​		775		20	%		9,223	​		6,951	​		2,272		33	%
Adjusted income before income taxes	​		18,356	​		20,967	​		(2,611)		(12)	%		26,012	​		33,980	​		(7,968)		(23)	%
Adjusted provision for income taxes ^(4)^	​		4,897	​		7,183	​		(2,286)		(32)	%		7,013	​		11,869	​		(4,856)		(41)	%
Adjusted net income	​	$	13,459	​	$	13,784	​	$	(325)		(2)	%	$	18,999	​	$	22,111	​	$	(3,112)		(14)	%
​	​		​	​		​	​		​			​		​	​		​	​					​
Adjusted net income per share	​		​	​		​	​		​			​		​	​		​	​					​
diluted	​	$	0.33	​	$	0.34	​	$	(0.01)		(2)	%	$	0.47	​	$	0.55	​	$	(0.08)		(14)	%
​	​		​	​		​	​					​		​	​		​	​					​
Weighted average common shares outstanding	​		​	​		​	​					​		​	​		​	​					​
diluted	​		40,504	​		40,504	​					​		40,504	​		40,504	​					​
​	​		​	​		​	​					​		​	​		​	​				​	​
Ratio to net sales	​		​	​		​	​					​		​	​		​	​					​
Adjusted gross profit	​		32.2	%		32.3	%		​			​		31.2	%		31.3	%					​
Adjusted selling, general and administrative	​		23.0	%		22.2	%					​		23.8	%		22.7	%					​
Adjusted income (loss) before income taxes	​		7.3	%		8.6	%					​		5.4	%		7.1	%					​
Adjusted net income (loss)	​		5.4	%		5.6	%					​		3.9	%		4.6	%					​
Adjusted effective tax rate	​		26.7	%		34.3	%					​		27.0	%		34.9	%					​

​

Certain amounts and percentages may reflect rounding adjustments.

* Calculation not meaningful

^(1)^ Adjusted cost of goods sold excludes acquisition-related intangible amortization and acquisition-related cost of goods sold

^(2)^Adjusted selling, general and administrative excludes acquisition-related intangible amortization, pension settlement cost, Brazil employment taxes, stock-based compensation and environmental remediation costs

^(3)^ Foreign currency losses (gains), net are excluded from adjusted net income

^(4)^ Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments and certain income tax items 25

Table of Contents

Comparison of three months ended December 31, 2023 and 2022

Net sales

Net sales of $249.9 million for the three months ended December 31, 2023, increased $5.3 million, or 2%, as compared to the three months ended December 31, 2022. Animal Health increased $9.3 million. Mineral Nutrition and Performance Products decreased $0.3 million and $3.7 million, respectively.

Animal Health

Net sales of $173.1 million for the three months ended December 31, 2023, increased $9.3 million, or 6%. Net sales of MFAs and other increased $4.8 million, or 5%, due to increased demand for our MFAs in international regions and for our processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products decreased $2.4 million, or 6%, mostly due to lower domestic dairy demand. Net sales of vaccines increased $7.0 million, or 31%, primarily due to poultry product introductions in Latin America, plus an increase in domestic demand.

Mineral Nutrition

Net sales of $61.3 million for the three months ended December 31, 2023, decreased $0.3 million, or less than 1%, primarily due to declines in average selling prices and some reduction in sales volume.

Performance Products

Net sales of $15.5 million for the three months ended December 31, 2023, decreased $3.7 million, or 19%, driven by decreased demand for personal care product ingredients and industrial chemicals.

Gross profit

Gross profit of $78.6 million for the three months ended December 31, 2023, increased $1.2 million, or 2%, as compared to the three months ended December 31, 2022. Gross margin decreased 10 basis points to 31.5% of net sales for the three months ended December 31, 2023, as compared to 31.6% for the three months ended December 31, 2022, due to decreased sales and unfavorable product mix in Mineral Nutrition and Performance Products.

Animal Health gross profit increased $4.1 million, primarily driven by higher sales volume and favorable product mix. Mineral Nutrition gross profit decreased $1.0 million, driven by lower sales volume and an increase in raw material costs. Performance Products gross profit decreased $1.6 million as a result of lower product demand and an increase in raw material costs. Acquisition-related cost of goods sold reduced gross profit by $0.3 million.

Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of $62.9 million for the three months ended December 31, 2023, increased $1.4 million, or 2%, as compared to the three months ended December 31, 2022. SG&A for the three months ended December 31, 2023, included a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes paid from January 2013 through December 2015, an additional $0.3 million true-up to the pension settlement cost and $0.1 million for stock-based compensation. SG&A for the three months ended December 31, 2022, included $6.6 million of environmental remediation costs. Excluding these items, SG&A increased $3.4 million, or 6%.

Animal Health SG&A increased $2.3 million, primarily due to an increase in employee-related costs to support increased demand in Latin America and Asia Pacific. Mineral Nutrition and Performance Products SG&A was comparable to the prior year. Corporate costs increased by $1.4 million, driven by the planned increase in strategic investments. 26

Table of Contents

Interest expense, net

Interest expense, net of $4.7 million for the three months ended December 31, 2023, increased by $0.8 million, as compared to the three months ended December 31, 2022, as a result of higher variable interest rates and slightly increased debt levels.

Foreign currency losses (gains), net

Foreign currency losses, net for the three months ended December 31, 2023, were $7.5 million, as compared to $(0.1) million of net gains for the three months ended December 31, 2022. Current period losses were driven by fluctuations in certain currencies related to the U.S. dollar, including a major devaluation in Argentina.

Provision for income taxes

The provision for income taxes was $2.3 million and $4.9 million for the three months ended December 31, 2023 and 2022, respectively. The effective income tax rates were 64.3% and 40.5% for the three months ended December 31, 2023 and 2022, respectively. The effective income tax rate for the three months ended December 31, 2023, increased due to an unfavorable mix of pre-tax income and related tax provisions in the various jurisdictions where we have operations and the relatively greater effect of certain items such as Global Intangible Low-Taxed Income (“GILTI”) on reduced pre-tax income.

Net income

Net income of $1.3 million for the three months ended December 31, 2023, decreased $5.9 million, as compared to net income of $7.2 million for the three months ended December 31, 2022. Operating income decreased $0.1 million, driven by higher SG&A, offset by favorable gross profit. Gross profit increased as a result of higher product demand in the Animal Health segment. SG&A included a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes paid from January 2013 through December 2015. Interest expense, net increased $0.8 million and foreign currency exchange resulted in increased losses of $7.6 million. Income tax expense increased by $2.6 million.

Adjusted EBITDA

Adjusted EBITDA of $29.5 million for the three months ended December 31, 2023, decreased $1.5 million, or 5%, as compared to the three months ended December 31, 2022. Animal Health Adjusted EBITDA increased $2.2 million due to gross profit from increased sales, partially offset by higher SG&A. Mineral Nutrition Adjusted EBITDA decreased $0.9 million, driven by lower gross profit. Performance Products Adjusted EBITDA decreased $1.5 million due to lower product demand and unfavorable product mix. Corporate expenses increased $1.3 million, driven by increased strategic investments.

Adjusted provision for income taxes

The adjusted provision for income taxes was $4.9 million and $7.2 million for the three months ended December 31, 2023 and 2022, respectively. The adjusted effective income tax rates were 26.7% and 34.3% for the three months ended December 31, 2023 and 2022, respectively. The improvement in our adjusted effective income tax rate for the three months ended December 31, 2023, was driven by a favorable mix of pre-tax income and the benefit of recently implemented global tax structuring.

Adjusted net income

Adjusted net income of $13.5 million for the three months ended December 31, 2023, decreased $0.3 million, or 2%, as compared to the prior year. Increased adjusted gross profit, driven by sales growth, was offset by higher adjusted SG&A and higher adjusted interest expense, net, with a partial benefit from a reduced adjusted provision for income taxes. Adjusted SG&A increased due to strategic investments and increased employee-related costs and adjusted interest expense, net, increased due to higher variable interest rates. 27

Table of Contents

Adjusted diluted earnings per share

Adjusted diluted earnings per share was $0.33 for the quarter, a decrease of $0.01, or 2% as compared to the adjusted diluted earnings per share of $0.34 in the prior year.

Comparison of six months ended December 31, 2023 and 2022

Net sales

Net sales of $481.3 million for the six months ended December 31, 2023, increased $4.1 million, or 1%, as compared to the six months ended December 31, 2022. Animal Health sales increased $15.0 million. Mineral Nutrition and Performance Products sales decreased $3.9 million and $6.9 million, respectively.

Animal Health

Net sales of $333.6 million for the six months ended December 31, 2023, increased $15.0 million, or 5%. Net sales of MFAs and other increased $6.1 million, or 3%, due to higher demand for processing aids used in the ethanol fermentation industry and for our MFAs in Latin America. Net sales of nutritional specialty products decreased $1.3 million, or 2%, driven by lower domestic dairy demand, partially offset by international poultry demand. Net sales of vaccines increased $10.2 million, or 22%, due primarily to poultry product introductions in Latin America, plus an increase in domestic demand.

Mineral Nutrition

Net sales of $117.4 million for the six months ended December 31, 2023, decreased $3.9 million, or 3%, driven by lower average selling prices and a reduction in sales volume.

Performance Products

Net sales of $30.3 million for the six months ended December 31, 2023, decreased $6.9 million, or 19%, driven by decreased demand for personal care product ingredients and industrial chemicals.

Gross profit

Gross profit of $146.3 million for the six months ended December 31, 2023, increased $0.3 million, as compared to the six months ended December 31, 2022. Gross margin decreased 20 basis points to 30.4% of net sales for the six months ended December 31, 2023, as compared to 30.6% for the six months ended December 31, 2022 due to decreased sales and unfavorable product mix in Mineral Nutrition and Performance Products.

Animal Health gross profit increased $6.6 million as a result of higher product demand. Mineral Nutrition gross profit decreased $3.3 million, driven by lower sales volume and an increase in raw material costs. Performance Products gross profit decreased $2.7 million due to lower demand and unfavorable product mix. Acquisition-related cost of goods sold reduced gross profit by $0.3 million.

Selling, general and administrative expenses

SG&A of $131.4 million for the six months ended December 31, 2023, increased $14.9 million, or 13%, as compared to the six months ended December 31, 2022. SG&A for the six months ended December 31, 2023, included $10.7 million pension settlement costs, a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes paid from January 2013 through December 2015, and $0.2 million of stock-based compensation. SG&A for the six months ended December 31, 2022, included $6.6 million of environmental remediation costs. Excluding these items, SG&A increased $6.4 million, or 6%.

Animal Health SG&A increased $3.7 million primarily due to an increase in employee-related costs and overall inflation. Mineral Nutrition SG&A remained relatively flat. Performance Products SG&A decreased $0.3 million, with a reduction in spending. Corporate expenses increased $3.0 million due to an increase in employee-related costs and strategic investments. 28

Table of Contents

Interest expense, net

Interest expense, net of $9.2 million for the six months ended December 31, 2023, increased $2.3 million, or 33%, as compared to the six months ended December 31, 2022, as a result of higher variable interest rates and increased debt levels.

Foreign currency losses, net

Foreign currency losses, net for the six months ended December 31, 2023, were $14.2 million, as compared to net losses of $5.1 million for the six months ended December 31, 2022. Current period losses were driven by fluctuations in certain currencies relative to the U.S. dollar, primarily related to a major devaluation in Argentina.

Provision for income taxes

The benefit for income taxes was $1.7 million for the six months ended December 31, 2023, and the provision for income taxes was $6.5 million for the six months ended December 31, 2022. The effective income tax rates were 19.9% and 36.9% for the six months ended December 31, 2023 and 2022, respectively. The effective income tax rate for the six months ended December 31, 2023, was unfavorably affected by the mix of pre-tax income and related tax provisions in the various jurisdictions where we have operations and the relatively greater effect of certain items such as GILTI on reduced pre-tax income. The provision for income taxes for the six months ended December 31, 2023, included (i) a $1.2 million benefit related to the determination of whether a foreign tax is eligible for a U.S. foreign tax credit related to our fiscal year 2023, based on Internal Revenue Service (“IRS”) guidance provided subsequent to our fiscal year-end, (ii) a $0.4 million benefit related to the release of certain valuation allowances on non-U.S. companies and (iii) a $0.3 million expense from changes in uncertain tax positions related to prior years. The effective income tax rate, without these discrete items, would have been 4.3% for the six months ended December 31, 2023. The provision for income taxes for the six months ended December 31, 2022, included a $0.9 million benefit related to exchange rate differences on intercompany dividends and a $0.2 million expense from changes in uncertain tax positions related to prior years. The effective income tax rate, without these items, would have been 41.0% for the six months ended December 31, 2022.

Net income

Net loss of $6.7 million for the six months ended December 31, 2023, decreased $17.8 million, as compared to net income of $11.1 million for the six months ended December 31, 2022. Operating income decreased $14.6 million driven by higher SG&A, slightly offset by higher gross profit. SG&A increased by $14.9 million due to pension settlement costs of $10.7 million and Brazil employment taxes of $4.2 million. Changes in interest expense, net and foreign currency losses resulted in a $2.3 million and $9.1 million reduction in income before income taxes, respectively. Income tax expense decreased $8.1 million.

Adjusted EBITDA

Adjusted EBITDA of $48.1 million for the six months ended December 31, 2023, decreased $4.9 million, or 9%, as compared to the six months ended December 31, 2022. Animal Health Adjusted EBITDA increased $3.8 million, resulting from higher sales and increased gross profit, partially offset by higher SG&A. Mineral Nutrition Adjusted EBITDA decreased $3.3 million, due to decreased sales and gross profit. Performance Products Adjusted EBITDA decreased $2.4 million, driven by decreased sales and gross profit. Corporate expenses increased $3.0 million due to increased employee-related costs and strategic investments.

Adjusted provision for income taxes

The adjusted provision for income taxes was $7.0 million and $11.9 million for the six months ended December 31, 2023 and 2022, respectively. The adjusted effective income tax rates for the six months ended December 31, 2023 and 2022, were 27.0% and 34.9%, respectively. The improvement in our adjusted effective income tax rate during the six months ended December 31, 2023, was driven by a favorable mix of pre-tax income and the benefit of recently implemented global tax structuring. 29

Table of Contents

Adjusted net income

Adjusted net income of $19.0 million for the six months ended December 31, 2023, decreased $3.1 million, or 14.1%, as compared to the prior year. The decrease was driven by higher adjusted SG&A and higher adjusted interest expense, net, partially offset by slightly improved adjusted gross profit and a partial benefit from a reduced adjusted provision for income taxes. Adjusted SG&A increased due to strategic investments and increased employee-related costs and adjusted interest expense, net, increased due to higher variable interest rates.

Adjusted diluted earnings per share

Adjusted diluted earnings per share was $0.47 for the six months ended December 31, 2023, a decrease of $0.08, or 14%, as compared to the adjusted diluted earnings per share of $0.55 in the prior year.

Analysis of financial condition, liquidity and capital resources

Net decrease in cash and cash equivalents was:

​

​	​	​	​	​	​	​	​	​	​
​	****	Six Months
For the Periods Ended December 31	****	2023		****	2022		****	Change
​	​	(in thousands)
Cash provided (used) by:	​	​	​	​	​	​	​	​	​
Operating activities	​	$	47,757	​	$	(13,187)	​	$	60,944
Investing activities	​		(40,213)	​		(25,959)	​		(14,254)
Financing activities	​		(13,409)	​		33,035	​		(46,444)
Effect of exchange-rate changes on cash and cash equivalents	​		(2,446)	​		285	​		(2,731)
Net decrease in cash and cash equivalents	​	$	(8,311)	​	$	(5,826)	​	$	(2,485)

Certain amounts may reflect rounding adjustments.

Net cash provided (used) by operating activities was comprised of:

​

​	​	​	​	​	​	​	​	​	​
​	****	Six Months
For the Periods Ended December 31	****	2023			2022		****	Change
​	​	(in thousands)
EBITDA	​	$	18,590	​	$	41,426	​	$	(22,836)
Adjustments:		​	​		​	​		​	​
Acquisition-related cost of goods sold	​	​	310	​	​	—	​	​	310
Pension settlement cost	​	​	10,674	​	​	—	​	​	10,674
Brazil employment taxes	​	​	4,202	​	​	—	​	​	4,202
Stock-based compensation		​	161		​	—		​	161
Environmental remediation costs	​	​	—	​	​	6,569	​	​	(6,569)
Foreign currency losses, net		​	14,166		​	5,051		​	9,115
Interest paid, net		​	(8,703)		​	(6,606)		​	(2,097)
Income taxes paid		​	(9,116)		​	(9,319)		​	203
Changes in operating assets and liabilities and other items		​	17,473		​	(50,308)		​	67,781
Net cash provided (used) by operating activities	​	$	47,757	​	$	(13,187)	​	$	60,944

Certain amounts may reflect rounding adjustments.

Operating activities

Operating activities provided $47.8 million of net cash for the six months ended December 31, 2023. Cash provided by net income (loss) and non-cash items, including depreciation and amortization, was $25.3 million. We paid $8.7 million of net interest expense and $9.1 million in income taxes, net. Cash provided in the ordinary course of business from changes in operating assets and 30

Table of Contents liabilities and other items was $17.5 million. Accounts receivable provided $14.3 million of cash due to timing of sales and an improvement in days sales outstanding. Inventories used $7.5 million of cash due to increased raw material and production costs, and increased quantities on hand due to forecasted future demand and internal production schedules. Accounts payable provided $11.5 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $2.4 million, primarily due to timing of incurrence and payments for professional fees.

Investing activities

Investing activities used $40.2 million of net cash for the six months ended December 31, 2023. Capital expenditures totaled $18.4 million, as we continue to invest in expanding production capacity and productivity improvements. Net purchases and maturities of our short-term investments used $19.5 million in cash. We acquired a business for $3.3 million, net of cash acquired.

Financing activities

Financing activities used $13.4 million of net cash for the six months ended December 31, 2023. Net borrowings on our 2021 Revolver provided $10.0 million in cash. We paid $13.7 million in scheduled debt maturities and insurance premium financing. We paid $9.7 million in dividends to holders of our Class A common stock and Class B common stock.

Liquidity and capital resources

We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under the 2021 Revolver and foreign credit lines, will be sufficient to support our ongoing cash needs. We are aware of the current and potential future effects of the macroeconomic market conditions in the financial markets. At this time, we expect adequate liquidity for at least the next twelve months. However, we can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will comply with the terms of the covenants under the 2021 Credit Facilities and foreign credit lines based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or ability to obtain future financing or fund operations or investment opportunities. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources follow:

​

​	​	​	​	​	​	​
​	****	December 31,		****	June 30,
As of	****	2023		****	2023
​	​	(in thousands, except ratios)
Cash and cash equivalents and short-term investments	​	$	92,493	​	$	81,281
Working capital	​		332,403	​		350,737
Ratio of current assets to current liabilities	​		3.06:1	​		3.28:1

​

We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

As of December 31, 2023, we had $151.0 million in outstanding borrowings under the 2021 Revolver and outstanding letters of credit and other commitments of $2.5 million, leaving $156.5 million available for further borrowings and letters of credit, subject to restrictions in our 2021 Credit Facilities.

We currently intend to pay quarterly dividends on our Class A common stock and Class B common stock, subject to approval from the Board of Directors. Our Board of Directors declared a cash dividend of $0.12 per share on Class A common stock and Class B common stock, payable on March 27, 2024. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions. 31

Table of Contents As of December 31, 2023, our cash and cash equivalents and short-term investments included $89.6 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries. Distributions may be subject to taxation by U.S. or non-U.S. taxing authorities.

Contractual obligations

As of December 31, 2023, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report.

Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

General description of non-GAAP financial measures

Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to reflect the results of our operations prior to considering certain income statement elements. We calculate EBITDA as net income (loss) plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (c) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income.

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

●	senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
●	our annual budgets are prepared on an Adjusted EBITDA basis; and
---	---
●	other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.
---	---

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income (loss), may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of acquired intangibles, and does not provide a comparable view of our performance to other companies. 32

Table of Contents

Adjusted net income and adjusted diluted earnings per share

Adjusted net income and adjusted diluted earnings per share represent alternative views of performance and we believe investors’ understanding of our performance is enhanced by disclosing these performance measures. We report adjusted net income (loss) and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. We calculate adjusted net income as net income (loss) plus (i) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, (ii) amortization of acquired intangibles and other acquisition-related costs, such as accrued compensation and accrued interest, (iii) stock-based compensation, (iv) certain items that we consider to be unusual or non-recurring and (v) the income tax effect of pre-tax income (loss) adjustments and certain income tax items. Adjusted diluted earnings per share is calculated using the adjusted net income divided by the diluted weighted average number of shares. The adjusted net income and adjusted diluted earnings per share measures are not, and should not be viewed as, a substitute for GAAP reported net income (loss).

Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measure that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of its non-standardized definition, adjusted net income and adjusted diluted earnings per share, unlike GAAP net income (loss), may not be comparable to the calculation of similar measures of other companies. Adjusted net income (loss) and adjusted diluted earnings per share are presented to permit investors to more fully understand how management assesses performance.

Certain significant items

Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis.

We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives, including employee separation costs, to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

New accounting standards

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”

Critical Accounting Policies

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended June 30, 2023, included in our Annual Report on Form 10-K filed with the Securities Exchange Commission on August 30, 2023. There have been no significant changes in our critical accounting estimates since June 30, 2023.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future 33

Table of Contents operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

●	outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials;
●	perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
---	---
●	restrictions on the use of antibacterials in food-producing animals may become more prevalent;
---	---
●	the potential FDA withdrawal of approval of our Mecadox^®^ (carbadox) product;
---	---
●	a material portion of our sales and gross profits are generated by antibacterials and other related products;
---	---
●	competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;
---	---
●	our business may be negatively affected by weather conditions and the availability of natural resources;
---	---
●	the negative effects of a pandemic, epidemic, or outbreak of an infectious disease in humans, such as COVID-19; on our business, financial results, manufacturing facilities and supply chain, as well as our customers, protein processors and markets;
---	---
●	climate change could have a material adverse impact on our operations and our customers’ businesses;
---	---
●	actions of regulatory bodies, including obtaining approvals related to the testing, manufacturing and marketing of certain of our products;
---	---
●	the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
---	---
●	our ability to control costs and expenses;
---	---
●	any unforeseen material loss or casualty;
---	---
●	misuse or extra-label use of our products;
---	---
●	exposure relating to rising costs and reduced customer income;
---	---
●	heightened competition, including those from generics and those deriving from advances in veterinary medical practices and animal health technologies;
---	---
●	unanticipated safety or efficacy concerns;
---	---
●	our dependence on suppliers having current regulatory approvals;
---	---
●	our raw materials are subject to price fluctuations and their availability can be limited;
---	---
●	natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
---	---

34

Table of Contents

●	business interruption from political and social instability, including crime, civil disturbance, terrorist activities, outbreaks of disease and pandemics and armed conflicts, such as the ongoing armed conflicts between Russia and Ukraine and Israel and Hamas;
●	terrorist attacks, particularly attacks on or within markets in which we operate, including the recent terrorist attack on Israel by Hamas militants and the ongoing related conflict;
---	---
●	risks related to changes in tax rates and exposure;
---	---
●	our ability to successfully implement our strategic initiatives;
---	---
●	our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
---	---
●	adverse U.S. and international economic market conditions, including currency fluctuations;
---	---
●	failure of our product approval, R&D, acquisition and licensing efforts to generate new products;
---	---
●	the risks of product liability claims, legal proceedings and general litigation expenses;
---	---
●	the impact of current and future laws and regulatory changes, including risks related to the protection of our customers’ privacy and risks related to environmental, health and safety laws and regulations;
---	---
●	modification of foreign trade policy may harm our food animal product customers;
---	---
●	our dependence on our Israeli and Brazilian operations;
---	---
●	impact of increased or decreased inventory levels at our direct customers or channel distributors;
---	---
●	our substantial level of indebtedness and related debt-service obligations;
---	---
●	restrictions imposed by covenants in our debt agreements;
---	---
●	the risk of work stoppages; and
---	---
●	other factors as described in “Risk Factors” in Item 1A of our Annual Report.
---	---

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

​ 35

Table of Contents Item 3.  Quantitative and Qualitative Disclosures about Market Risk

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. As of the date of this report, there were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

​

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarter ended December 31, 2023.

​

PART II—OTHER INFORMATION

Item 1.Legal Proceedings

Information required by this Item is incorporated herein by reference to “Notes to Consolidated Financial Statements—Commitments and Contingencies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.

​

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in Item 1A of our Annual Report, which could materially affect our business, financial condition or future results.

There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.

​

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

None.

​

Item 3.Defaults Upon Senior Securities

None.

​ 36

Table of Contents

Item 4.Mine Safety Disclosures

Not applicable.

​

Item 5. Other Information

None.

​

Item 6.Exhibits

​	​	​
Exhibit 31.1		Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 31.2	​	Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302
Exhibit 32.1	​	Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Exhibit 32.2	​	Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906
Exhibit 101.INS	​	Inline XBRL Instance Document
Exhibit 101.SCH	​	Inline XBRL Taxonomy Extension Schema Document
Exhibit 101.CAL	​	Inline XBRL Taxonomy Extension Calculation Linkbase Document
Exhibit 101.DEF	​	Inline XBRL Taxonomy Extension Definition Linkbase Document
Exhibit 101.LAB	​	Inline XBRL Taxonomy Extension Label Linkbase Document
Exhibit 101.PRE	​	Inline XBRL Taxonomy Extension Presentation Linkbase Document
Exhibit 104	​	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

​

​

​ 37

Table of Contents SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​	Phibro Animal Health Corporation
​	​
February 7, 2024	By:	/s/ Jack C. Bendheim
​	​	Jack C. Bendheim
​	​	Chairman, President and Chief Executive Officer
​	​
February 7, 2024	By:	/s/ Richard G. Johnson
​	​	Richard G. Johnson
​		Chief Financial Officer

​

​

​ 38

EXHIBIT 31.1

CERTIFICATIONS

I, Jack C. Bendheim, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Phibro Animal Health Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

​

​	​
Dated: February 7, 2024	/s/ Jack C. Bendheim
​	Jack C. Bendheim
​	Chairman, President and Chief Executive Officer

​

EXHIBIT 31.2

CERTIFICATIONS

I, Richard G. Johnson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Phibro Animal Health Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

​

​	​
Dated: February 7, 2024	/s/ Richard G. Johnson
​	Richard G. Johnson
​	Chief Financial Officer

​

EXHIBIT 32.1

CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this periodic report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this periodic report fairly presents, in all material respects, the financial condition and results of operations of the issuer.

​

Dated: February 7, 2024	/s/ Jack C. Bendheim
​	Jack C. Bendheim
​	Chairman, President and Chief Executive Officer

​

EXHIBIT 32.2

CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this periodic report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this periodic report fairly presents, in all material respects, the financial condition and results of operations of the issuer.

​

​	​
Dated: February 7, 2024	/s/ Richard G. Johnson
​	Richard G. Johnson
​	Chief Financial Officer

​